Summary Plasma prolactin (PRL) and carcinoembryonic antigen (CEA) were measured by radioimmunoassay in 74 patients with adenocarcinoma of colon and rectum. The markers were correlated with disease stage, histological grade and progression/remission of disease. The circulating preoperative median PRL and CEA levels were significantly higher in colorectal cancer patients than in their respective controls. PRL was elevated in all Dukes stages and in all histological grades of the tumour whereas the rise in CEA was more pronounced in Dukes D. Out of 74 patients, 29% (21/74) developed recurrent disease and 31% (23/74) responded to the treatment. With regard to monitoring recurrence(s), the predictive value of PRL was 94% which was significantly greater than that of CEA which was only 62%. In patients who developed liver metastases PRL remained elevated whereas CEA showed more than 100-fold increase. Therefore, we feel that CEA is a better marker for monitoring patients who developed liver metastases. From our results, we suggest that PRL can be used as a better overall marker for detecting recurrence(s) in patients with colorectal adenocarcinoma.
Recently, we have published data on circulating prolactin levels in patients with breast cancer (80% of these had advanced disease i.e. with stage III and IV). The data mainly concern relationship between circulating prolactin and histologic grade, estrogen-and progesterone-receptor (ER, PR) and 2 years postoperative survival (Bhatavdekar et al., 1990a) . We have also found plasma prolactin useful both as an indicator of disease progression and as short-term prognosticator in patients with advanced breast cancer (Bhatavdekar et al., 1990b; 1992) . In light of the interesting and convincing results obtained by us in breast cancer patients, we have now tested the significance of prolactin in colorectal cancer, another common cancer in this region, by comparing simultaneously prolactin results with those of CEA.
In this study therefore, we have compared the sensitivity and specificity of prolactin and CEA and thus the relative usefulness of these markers in monitoring recurrences in patients with colorectal adenocarcinomas. In addition, plasma prolactin and CEA levels were also correlated with disease stage and histologic grade. Blood collection Blood samples were collected in EDTA, disodium salt coated tubes (1-2 mg ml-') for prolactin (PRL) and CEA estimations strictly between 9.0 and 11.0 a.m. preoperatively and at monthly intervals thereafter. The plasma was separated within 1-2 h of collection, aliquoted and stored at -70°C. Assays were carried out within 1 month of collection.
Pathological examination
Disease was staged using Dukes system (Dukes & Bussey, 1958 Plasma PRL and CEA were assayed using double antibody RIA kits (Diagnostic Products Co., USA). The assays were performed in duplicate with an intra-and inter-assay coefficient of variation (CV) of 3-5% and 5-8% respectively. PRL values > 15.0 ng ml-' for males, > 20.0 ng ml-' for premenopausal and > 10.0 ng ml-' for postmenopausal females were considered for % elevation. CEA levels above 5.0 ng ml-' was regarded as % elevated.
Criteria for positive tests were: continual rise in the marker level after an initial fall or persistent high level of the marker as an indicator of relapse and/or no response to treatment.
Statistical analysis
The statistical significance of differences between various groups was calculated by Mann-Whitney U-test. a-value <0.05 (two tailed test) were considered statistically significant. Karl-Pearson correlation coefficient (r) was used to calculate correlation between two parameters. Sensitivity, specificity and predictive values were calculated as described by Tondini et al. (1988) .
Results
Preoperative plasma PRL and CEA levels for controls and colorectal cancer patients are shown in Table I . No correlation was observed bewteen two markers (r = + 0.037). Median marker levels were significantly elevated in colorectal carcinoma patients. Table II shows the distribution of patients according to Dukes stages. Sixty-three percent of our patients had advanced disease (C and D). Median PRL level in male patients was higher in Dukes B and C than in D (Figure 1 ). Dukes D patients showed higher CEA levels than A, B and C (Figure 2) .
The median levels of PRL and CEA were more or less similar in all the three grades of the tumour. This may be due to the fact that 91% patients had histologic grade II and III tumour.
Markers in responders
All patients who responded to various therapeutic modalities at the end of 2 years showed decreased PRL and CEA levels. The difference was statistically significant only for PRL (Table III) . Non-progressive elevation of CEA was seen in 7/23 (30%). n Markers in patients who developed recurrence On sequential follow-up, the PRL levels reduced at response whereas with the appearance of local/distant metastases, the PRL levels increased significantly (Table III) . It was observed that the rise in PRL preceded disease progression by approximately 2-3 months. Moreover, PRL levels also remained elevated through out the course of disease in patients who did not respond to adjuvant therapy (Figure 3 ). On sequential follow-up, CEA levels reduced with remission whereas with appearance of recurrence, the CEA levels increased only in 17/21 (81%) patients (Table III) . In patients with Dukes D, as the disease progressed PRL remained elevated but CEA showed remarkable increase (Figure 4) . Figure 3 Patient had Dukes C grade II tumour and 14/16 metastatic pararectal lymph nodes. Post-operative chemotherapy was given. He responded to it. He was without any complaints for nearly 7 months. At the end of 1st year, he developed lung metastasis. Second line chemotherapy was instituted but he did not respond to it and finally died. PRL showed lead time and correlated excellently with disease remission and progression. CEA was less than 5.0 ng ml-throughout the disease course. Figure 4 Dukes D patient with metastasis in the liver. Postoperative CEA decreased while PRL was elevated. She was given palliative CT to which she did not respond. Both the markers correlated well with the disease status. PRL remained elevated whereas 100-fold increase was observed for CEA. (---CEA; PRL).
Discussion
The (Moertel et al., 1978; Ovaska et al., 1990) have found it less sensitive and therefore unsatisfactory whereas Staab et al. (1985) found it quite reliable. The present study, however, suggests that CEA may be of little practical value in local/distant metastases. Even in patients who developed recurrence(s), CEA remained <5.0 ng ml-' plasma in 24% of patients throughout the course of the disease. In such patients, PRL accurately predicted disease progression (Figure 3) . Moreover, temporary, nonprogressive elevations of CEA were seen in 30% of patients, which is an extreme example of this phenomenon (Rittgers et al., 1978) . Despite the lack of specificity for colon cancer, CEA demonstrated an excellent correlation in patients with colorectal liver metastases (Chu et al., 1982; DeBrauw et al., 1987; Lorenz et al., 1989; Chang et al., 1989) . Our study confirms these findings with 100% score. In these patients PRL remained high.
On the basis of the present encouraging results, we support that CEA lacks sufficient sensitivity and specificity to detect occult recurrence(s). CEA is most useful in monitoring patients who developed liver metastases. On the contrary, plasma PRL is a very important independent predictor of recurrent disease which may be due to higher sensitivity, specificity and significantly higher predictive values.
